Shares of Bausch Health Companies Inc. BHC gained 12.6% after the company reported better-than-expected third-quarter results ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Steve Scala, an analyst from TD Cowen, maintained the Hold rating on Bausch Health Companies (BHC – Research Report). The associated ...
Bausch Health shares rose Thursday morning after the company raised its full year outlook following a better-than-expected third-quarter performance. Shares traded over 11% higher in Toronto at 12.68 ...
Bausch Health Companies (NYSE:BHC – Free Report) had its price target increased by Royal Bank of Canada from $10.00 to $11.00 ...
"Our team at Bausch Health continued to execute against our commitments in ... These results reflect the strength of our diverse and robust portfolio of products, both geographically and across ...
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of ...
For Bausch Health, excluding Bausch + Lomb ... Latin America and Canada, broad portfolio of products, as we reported this quarter, growing very nicely. We continue to focus to do business ...
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Shares of Bausch Health Companies Inc. BHC gained 12.6% ... International, Diversified Products, Solta Medical and Bausch + Lomb. Salix revenues totaled $642 million, up 5% year over year.